Surgery Websites
Lobular Breast Cancer Research Program »  People »  Principal Investigator »  Rita Mukhtar, M.D.
Rita Mukhtar, M.D.

Rita Mukhtar, M.D.

Associate Professor of Surgery
Division of Surgical Oncology

Contact Information

Open Popup

1996-2000 University of California, Berkeley, AB Molecular and Cell Biology

2001-2006 University of California, San Francisco, MD

  • 2006-2012 University of California, San Francisco, Resident, General Surgery
  • 2012-2013 University of California, San Francisco, Chief Resident, General Surgery
  • 2009-2011 University of California, San Francisco, Post-doctoral Research Fellow
  • 2013-2014 University of California, San Francisco, Society of Surgical Oncology Fellow, Breast Surgery
  • 2009-2010 UCSF CTSI Advanced Training in Clinical Research
  • American Board of Surgery, General Surgery
  • Carol Franc Buck Breast Care Center
  • Axillary dissection
  • Breast Surgery
  • Emergency General Surgery
  • Lumpectomy
  • Nipple sparing/total skin sparing mastectomy
  • Seed and wire localization surgery
  • Sentinel lymph node biopsy

Breast oncologic surgeon-scientist Rita Mukhtar, M.D., Associate Professor of Surgery at UCSF, leads clinical and translational research on invasive lobular carcinoma (ILC), the second most common type of breast cancer, and an understudied disease with unique treatment challenges. Funded by the American Cancer Society and the Helen Diller Comprehensive Cancer Center, Dr. Mukhtar studies surgical outcomes and treatment response predictors in ILC. Additionally, she is the UCSF Principle Investigator for a surgical window trial testing pre-operative endocrine therapy in ILC. Dr. Mukhtar collaborates with a multidisciplinary team from The Helen Diller Family Comprehensive Cancer Center to advance ILC research and innovate targeted treatment strategies that improve patient lives and outcomes.

Dr Mukhtar completed her undergraduate education at UC Berkeley, where she studied music and molecular biology. She then attended medical school at UCSF, during which time she received a Doris Duke Clinical Research Fellowship and pursued research in the inflammatory response in sepsis, winning a resident research award. She remained at UCSF for General Surgery residency, and completed a two year post-doctoral research fellowship focusing on the role of inflammatory cells in breast cancer outcomes, funded by the California Breast Cancer Research Program.

During this time she received a scholarship from the UCSF Clinical and Translational Science Institute to complete a certificate in Advanced Training in Clinical Research. After residency, she completed a fellowship in breast oncologic surgery. She currently practices breast surgery, including treatment of benign and malignant breast disease, and acute care general surgery.

Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 67
Data provided by UCSF Profiles, powered by CTSI
  1. Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. NPJ Breast Cancer. 2021 Dec 21; 7(1):156. View in PubMed
  2. Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, Desmedt C, Benz C, Mukhtar RA. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Res Treat. 2021 Nov 24. View in PubMed
  3. Naila Dhanani, Oscar Olavarria, Kyung Hyun Lee, Charlotte Young, Frank Primus, Rita Mukhtar, Julie Holihan, Mike Liang, Hobart Harris. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR. British Journal of Surgery. 2021 Nov 24; 108(Supplement_8). View in PubMed
  4. Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139. View in PubMed
  5. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. View in PubMed
  6. View All Publications

 

Site Directory
    X